BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» Galapagos, Merck in Potential €170M Obesity, Diabetes Deal
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Galapagos, Merck in Potential €170M Obesity, Diabetes Deal
Jan. 12, 2009
No Comments
No AbstractMechelen, Belgium-based Galapagos NV signed its fifth major pharmaceutical alliance, inking a potential €171.5 million (US$230.4 million)-plus deal with Merck & Co. Inc. to develop drugs aimed at the obesity and diabetes markets.
BioWorld